vVARDIS, a trailblazer in biomimetic dental innovations founded in Switzerland by Dr. Haley Abivardi and Dr. Goly Abivardi, has proudly announced the successful raising of $35,000,000 in its latest funding round. With more than 25 years of research and over 30 years of dental and entrepreneurial experience, the company is committed to making a transformative impact on oral health worldwide. Under its renowned CURODONT brand, vVARDIS has developed breakthrough dental products centered on its proprietary biomimetic peptide technology, exemplified by its flagship solution, Curodont Repair. This innovative product is backed by over 200 scientific publications and has gained endorsements from leading universities and key opinion leaders. It offers dental professionals a non-invasive, quick, and pain-free approach to arrest and reverse early caries, facilitating the in-depth regeneration of tooth enamel and the preservation of natural tooth structure.
The newly secured funds will be strategically allocated to accelerate the global expansion of vVARDIS’s groundbreaking solutions. Investments will be made to bolster further research and development, enhance marketing efforts, and extend educational initiatives among dental practitioners, ensuring that the benefits of this technology reach a broader audience. By supporting early medical intervention against tooth decay for patients of all ages, the funding will not only catalyze innovations in dental care but also advance the company’s vision of creating a world where caries treatment is accessible, regenerative, and pain-free. With this infusion of capital, vVARDIS is well-positioned to continue its mission of transforming oral healthcare, one smile at a time—because at vVARDIS, we believe that saving teeth truly saves lives.
